Where does CSL Behring Gene Therapy, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), CSL Behring Gene Therapy, Inc. ranks #45,951 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does CSL Behring Gene Therapy, Inc. hold?

CSL Behring Gene Therapy, Inc. holds 5 US utility patents granted between 2021 and 2023, spanning 6 technology areas.

What is CSL Behring Gene Therapy, Inc.'s Innovation Score?

CSL Behring Gene Therapy, Inc. has an Innovation Score of 34.9 out of 100 (49th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does CSL Behring Gene Therapy, Inc. focus on?

CSL Behring Gene Therapy, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 5 patents, ranking #3,434 of 6,058 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is CSL Behring Gene Therapy, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for CSL Behring Gene Therapy, Inc..

What does claim depth mean for CSL Behring Gene Therapy, Inc.'s patents?

CSL Behring Gene Therapy, Inc.'s patents average 16.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the CSL Behring Gene Therapy, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

CSL Behring Gene Therapy, Inc.

USPTO PatentsView assignee record - 5 granted patents across 6 technology areas, recorded in grant years 2021–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, CSL ranks #45,951 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 6 technology areas.

#45,951
of 49,997 US assignees by volume: 49th percentile
by Innovation Score (34.9/100): 16.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R45951 · US Corporation #45,951 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 5 grants
BOTTOM-DECILE #45,951/49,997
PHOTO-FINISH CS Tech Holdings
CPC-NARROW A61P · 6 areas
INNOV-THIN 34.9/100
CLAIMS-RICH 16.8 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2021–2023 · 3y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: CS Tech Holdings LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How CSL’s 34.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.2 pts (18%) Velocity 10.0 pts (29%) Breadth 8.7 pts (25%) Claim depth 10.1 pts (29%)

Qualcomm Incorporated · highest

85
CSL Behring Gene… · this assignee

35
3D Lighting… · lowest

7

What this shows CSL's Innovation Score is 34.9/100 (49th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for CSL?

Each dot is one of CSL’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). CSL’s own 16.8 claims/patent is ABOVE the 13.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

CSL vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where CSL's grants concentrate

CSL Behring Gene Therapy, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (2 grants) versus a trough of 1 in 2023. By volume, CSL sits between CS Tech Holdings LLC and Ctpg Operating, LLC.

CSL's three-year grant acceleration

CSL Behring Gene Therapy, Inc. shows 3 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

CS Tech Holdings

5
CSG Systems

5
CSI Enterprises

5
Csic Pride (Nanji…

5
CSP

5
CTC—Centro de Tec…

5
Ctek Sweden AB

5
Ctpg Operating

5
CSL Behring Gene… ◀

5

What this shows CSL holds 5 patents at rank #45,676, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near CSL

By rank, the assignees closest to #45,676 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in CSL's primary technology class.

CSL's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 49th percentile higher than 49% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

CSL Behring Gene Therapy, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	2	40.0%
2022	2	40.0%
2023	1	20.0%

Which technologies does CSL Behring Gene Therapy, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 5

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 5

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

C12Y - Enzymes 2

C07K - Peptides 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

CSL Behring Gene Therapy, Inc.'s patent record in context - here's where to go next.

CSL Behring Gene Therapy, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #45,951 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare CSL Behring Gene Therapy, Inc. against CS Tech Holdings LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.